A role for oncostatin M in inflammatory bowel disease

被引：23
作者：
Kim, Walter M. [1 ]
Kaser, Arthur [2 ]
Blumberg, Richard S. [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gastroenterol, Boston, MA 02115 USA
[2] Univ Cambridge, Dept Med, Div Gastroenterol & Hepatol, Cambridge, England
来源：
NATURE MEDICINE | 2017年 / 23卷 / 05期
关键词：
MAINTENANCE THERAPY; ULCERATIVE-COLITIS; CROHNS-DISEASE; INDUCTION; VEDOLIZUMAB;
D O I：
10.1038/nm.4338
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
A new study identifies oncostatin M (OSM) as a potential biomarker and therapeutic target for anti-tumor necrosis factor (TNF)-refractory inflammatory bowel disease (IBD), and pinpoints mucosal stromal cells as key players in OSM-mediated inflammation.
引用
收藏
页码：535 / 536
页数：2
相关论文
共 50 条
  • [41] The role of antibiotics in inflammatory bowel disease
    Triantafillidis, J. K.
    Triantafillidis, Aikaterini
    ANNALS OF GASTROENTEROLOGY, 2008, 21 (01): : 17 - 26
  • [42] Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab
    Dupre, Anastasia
    Collins, Michael
    Nocturne, Gaetane
    Carbonnel, Franck
    Mariette, Xavier
    Seror, Raphaele
    RHEUMATOLOGY, 2020, 59 (11) : 3275 - 3283
  • [43] Emerging treatments for inflammatory bowel disease
    Hazel, Karl
    O'Connor, Anthony
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2020, 11
  • [44] Inflammatory Bowel Disease in the Older Adult
    Cohen-Mekelburg, Shirley
    Waljee, Akbar K.
    CLINICS IN GERIATRIC MEDICINE, 2021, 37 (01) : 185 - 195
  • [45] The Gut Microbiota in Inflammatory Bowel Disease
    Qiu, Peng
    Ishimoto, Takatsugu
    Fu, Lingfeng
    Zhang, Jun
    Zhang, Zhenyong
    Liu, Yang
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [46] The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease
    Mantaka, Aikaterini
    Tsoukali, Emmanouela
    Fragkaki, Maria
    Karmiris, Konstantinos
    Viazis, Nikos
    Mantzaris, Gerassimos J.
    Koutroubakis, Ioannis E.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 32 (05) : 581 - 587
  • [47] Use of Precision Medicine in Clinical Trials in Inflammatory Bowel Disease
    Khanna, Reena
    Vande Casteele, Niels
    INFLAMMATORY BOWEL DISEASES, 2019, 25 (02) : 213 - 216
  • [48] Medical Management of Inflammatory Bowel Disease
    Rahman, Shahrose
    Patel, Ranish K.
    Boden, Elisa
    Tsikitis, Vassiliki Liana
    SURGICAL CLINICS OF NORTH AMERICA, 2024, 104 (03) : 657 - 671
  • [49] Vedolizumab (Entyvio) for Inflammatory Bowel Disease
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2014, 56 (1451): : 86 - 88
  • [50] Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin
    Cao, Ying
    Dai, Yibei
    Zhang, Lingyu
    Wang, Danhua
    Hu, Wen
    Yu, Qiao
    Wang, Xuchu
    Yu, Pan
    Liu, Weiwei
    Ping, Ying
    Sun, Tao
    Sang, Yiwen
    Liu, Zhenping
    Chen, Yan
    Tao, Zhihua
    JOURNAL OF INFLAMMATION RESEARCH, 2021, 14 : 6409 - 6419
12345